MPC Member Publications

This database contains a listing of population studies publications written by MPC Members. Anyone can add a publication by an MPC student, faculty, or staff member to this database; new citations will be reviewed and approved by MPC administrators.

Full Citation

Title: Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United States

Citation Type: Journal Article

Publication Year: 2022

ISSN: 1097-0142

DOI: 10.1002/CNCR.34462

PMID: 36126024

Abstract: Background: Cytomegalovirus (CMV) is among the most common viral infections after solid organ transplantation (SOT). Associations of CMV with cancer risk among SOT recipients have been incompletely evaluated. Methods: The authors used linked data from the US SOT registry and 32 cancer registries. Poisson regression was used to compare cancer incidence across CMV risk groups based on donor (D) and recipient (R) immunoglobulin G (IgG) serostatus: high risk (R-negative/D-positive), moderate risk (R-positive), and low risk (R-negative/D-negative). Results: In total, 247,318 SOT recipients were evaluated during 2000–2017 (R-negative/D-positive, 20.3%; R-positive, 62.9%; R-negative/D-negative, 16.8%). CMV-seropositive recipients were older, more racially/ethnically diverse, and had lower socioeconomic status than CMV-seronegative recipients. Compared with R-negative/D-negative recipients, recipients in the R-negative/D-positive and R-positive groups had a lower incidence of diffuse large B-cell lymphoma (DLBCL; R-negative/D-positive: adjusted incidence rate ratio [aIRR], 0.74; 95% confidence interval [CI], 0.59–0.91; R-positive: aIRR, 0.83; 95% CI, 0.69–1.00). CMV serostatus modified the association between Epstein–Barr virus (EBV) status and DLBCL (p =.0006): DLBCL incidence was increased for EBV R-negative/D-positive recipients (aIRR, 3.46; 95% CI, 1.50–7.95) among CMV R-negative/D-negative recipients but not among the other CMV risk groups. Compared with recipients who were CMV R-negative/D-negative, those who were R-negative/D-positive had a lower incidence of small intestine cancer (aIRR, 0.23; 95% CI, 0.09–0.63), and R-positive recipients had a higher incidence of lung cancer (aIRR, 1.24; 95% CI, 1.05–1.46). CMV status was not associated with risk for other cancers. Conclusions: CMV status was not associated with risk for most cancers among SOT recipients. The inverse association with DLBCL may reflect the protective effects of CMV prophylaxis or treatment with off-target efficacy against EBV infection (the major cause of lymphoma in SOT recipients).

Url: https://pubmed.ncbi.nlm.nih.gov/36126024/

User Submitted?: No

Authors: Geris, Jennifer M.; Spector, Logan G.; Pfeiffer, Ruth M.; Limaye, Ajit P.; Yu, Kelly J.; Engels, Eric A.

Periodical (Full): Cancer

Issue:

Volume:

Pages:

Countries:

IPUMS NHGIS NAPP IHIS ATUS Terrapop